[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hee-Jin Kim\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100604820","phase-2-investigator-initiated-study-for-the-safety-and-efficacy-in-frontotemporal-dementia-100604820",false,"NCT07154485","Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia","A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Investigator-initiated Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD), and Exploratory Efficacy of Multiple Doses of NS101 in Patients With Semantic Variant Primary Progressive Aphasia (svPPA), a Subtype of Frontotemporal Dementia (FTD)","Key Inclusion Criteria:\n\n* Participants diagnosed at screening with mild to moderate frontotemporal dementia, semantic variant (svFTD), defined by a CDR® Plus NACC FTLD Sum of Boxes (SOB) score between 4.5 and 15.5.\n* Participants confirmed to be amyloid-negative based on Amyloid PET scan or CSF results within the past 36 months.\n\nKey Exclusion Criteria:\n\n* Participants with other degenerative brain diseases as determined by the investigator\n* Participants with other neurological disorders and uncontrolled acute disease","ALL","55 Years","80 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics\u002Fpharmacodynamics (PK\u002FPD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)",[27],"Dementia Frontotemporal",[29,30,31,32,33,34],"Frontotemporal Dementia","semantic variant","FTD","sv FTD","PPA","sv PPA","NOT_YET_RECRUITING","2025-09-03",{"date":38,"type":39},"2025-09-04","ACTUAL",{"date":41,"type":21},"2025-10-01",{"date":43,"type":21},"2028-08-01",{"name":45,"class":46},"Hee-Jin Kim","OTHER",""]